Cargando…
Drug repurposing strategies for COVID-19
COVID-19 has now been declared a pandemic and new treatments are urgently needed as we enter a phase beyond containment. Developing new drugs from scratch is a lengthy process, thus impractical to face the immediate global challenge. Drug repurposing is an emerging strategy where existing medicines,...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Newlands Press Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117595/ http://dx.doi.org/10.4155/fdd-2020-0010 |
_version_ | 1783514403430203392 |
---|---|
author | Senanayake, Suranga L |
author_facet | Senanayake, Suranga L |
author_sort | Senanayake, Suranga L |
collection | PubMed |
description | COVID-19 has now been declared a pandemic and new treatments are urgently needed as we enter a phase beyond containment. Developing new drugs from scratch is a lengthy process, thus impractical to face the immediate global challenge. Drug repurposing is an emerging strategy where existing medicines, having already been tested safe in humans, are redeployed to combat difficult-to-treat diseases. While using such repurposed drugs individually may ultimately not yield a significant clinical benefit, carefully combined cocktails could be very effective, as was for HIV in the 1990s; the urgent question now being which combination. |
format | Online Article Text |
id | pubmed-7117595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Newlands Press Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-71175952020-04-02 Drug repurposing strategies for COVID-19 Senanayake, Suranga L Future Drug Discov Editorial COVID-19 has now been declared a pandemic and new treatments are urgently needed as we enter a phase beyond containment. Developing new drugs from scratch is a lengthy process, thus impractical to face the immediate global challenge. Drug repurposing is an emerging strategy where existing medicines, having already been tested safe in humans, are redeployed to combat difficult-to-treat diseases. While using such repurposed drugs individually may ultimately not yield a significant clinical benefit, carefully combined cocktails could be very effective, as was for HIV in the 1990s; the urgent question now being which combination. Newlands Press Ltd 2020-03-25 2020-03 /pmc/articles/PMC7117595/ http://dx.doi.org/10.4155/fdd-2020-0010 Text en © 2020 Suranga L Senanayake This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Editorial Senanayake, Suranga L Drug repurposing strategies for COVID-19 |
title | Drug repurposing strategies for COVID-19 |
title_full | Drug repurposing strategies for COVID-19 |
title_fullStr | Drug repurposing strategies for COVID-19 |
title_full_unstemmed | Drug repurposing strategies for COVID-19 |
title_short | Drug repurposing strategies for COVID-19 |
title_sort | drug repurposing strategies for covid-19 |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117595/ http://dx.doi.org/10.4155/fdd-2020-0010 |
work_keys_str_mv | AT senanayakesurangal drugrepurposingstrategiesforcovid19 |